<DOC>
	<DOCNO>NCT01957176</DOCNO>
	<brief_summary>This study provide continued access treatment eltrombopag subject currently participate GlaxoSmithKline ( GSK ) sponsor investigational study eltrombopag ( parent study ) collect long term safety data .</brief_summary>
	<brief_title>A Rollover Study Provide Continued Treatment With Eltrombopag</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Written inform consent obtain subject ( subject 's legally acceptable representative ) prior performance studyspecific procedure . The subject participate GSK sponsor investigational study eltrombopag ( parent study ) within past 28 day receive clinical benefit without unacceptable toxicity determine investigator . Subjects QTc &lt; 450 millisecond ( msec ) &lt; 480 msec subject bundle branch block . The QTc QT interval correct heart rate accord either Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) another method , machine manual overread . For subject eligibility withdrawal QTcF use . For purpose data analysis , QTcF use . The QTc base single average QTc value triplicate electrocardiogram ( ECGs ) obtain brief recording period . Women must either nonchild bear potential woman childbearing potential men reproductive potential must willing practice acceptable method birth control study . Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , study 4 week follow last dose study treatment . Men female partner childbearing potential must either prior vasectomy agree use effective contraception time first dose 16 week last dose study treatment . In France , subject eligible inclusion study either affiliate , beneficiary , social security category . Permanent discontinuation eltrombopag parent study base upon study treatment discontinuation study withdrawal criterion parent study . Subjects permanently discontinue treatment complete study related treatment remain eligible . The subject pregnant lactate female . Any serious and/or unstable preexist medical , psychiatric disorder condition time transition study could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK Medical Monitor . French subject : The French subject participate study use investigational drug previous 30 day , exception eltrombopag , parent study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>, idiopathic thrombocytopenic purpura</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>pediatrics</keyword>
</DOC>